Last Price$70.5(2.1%)
Market Cap$13.4B
EV/Revenue LTM
4.4x
5Y avg
7.9x
Biotechnology industry
median
3.7x
Stock quality & Intrinsic value
7/10
(0.3%) overvalued
BioMarin Pharmaceutical Inc. EV/Revenue LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EV/Revenue LTM | 31.9x | 21.0x | 35.0x | 6.6x | 6.0x | 8.7x | 9.3x | 12.4x | 18.1x | 20.0x | 19.1x | 13.3x | 12.4x | 9.8x | 9.6x | 8.4x | 8.8x | 9.5x | 7.9x | 4.4x |
Overvalued or undervalued?
Check the intrinsic value for BMRN
and see if it's the right time to invest.
BioMarin Pharmaceutical Inc. (BMRN) EV/Revenue LTM comparison analysis
General
LTM EV/Revenue LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
BioMarin Pharmaceutical Inc.BMRN
4.5x
18.0%
139.3%
15.0%
Median Peer Set
3.3x
13.2%
(41.2%)
0.4%
Alnylam Pharmaceuticals, Inc.ALNY
13.0x
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals IncorporatedVRTX
10.9x
11.7%
N/A
(4.9%)
Royalty Pharma plcRPRX
9.0x
(3.8%)
(43.7%)
37.9%
Regeneron Pharmaceuticals, Inc.REGN
4.3x
8.3%
10.4%
31.1%
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
Incyte CorporationINCY
2.8x
14.8%
(94.0%)
0.8%
BioNTech SEBNTX
2.0x
(77.4%)
(89.7%)
24.4%
BeiGene, Ltd.BGNE
0.1x
73.7%
467.1%
(35.9%)
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
BMRN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 25.7 37.7% | 84.2 228.1% | 121.6 44.4% | 296.5 143.9% | 324.7 9.5% | 376.3 15.9% | 441.4 17.3% | 500.7 13.5% | 548.5 9.5% | 751.0 36.9% | 889.9 18.5% | 1,116.9 25.5% | 1,313.6 17.6% | 1,491.2 13.5% | 1,704.0 14.3% | 1,860.5 9.2% | 1,846.3 (0.8%) | 2,096.0 13.5% | 2,419.2 15.4% | 2,853.9 18.0% |
| Cost of Goods Sold (COGS) | 2.6 | 8.7 | 18.4 | 52.5 | 65.9 | 70.3 | 84.0 | 91.8 | 95.7 | 129.8 | 152.0 | 209.6 | 241.8 | 315.3 | 359.5 | 524.3 | 470.5 | 483.7 | 577.1 | 580.2 |
% margin | 23.0 89.8% | 75.5 89.6% | 103.2 84.9% | 244.0 82.3% | 258.7 79.7% | 306.0 81.3% | 357.3 81.0% | 408.9 81.7% | 452.7 82.5% | 621.3 82.7% | 737.9 82.9% | 907.2 81.2% | 1,071.9 81.6% | 1,175.9 78.9% | 1,344.6 78.9% | 1,336.2 71.8% | 1,375.8 74.5% | 1,612.4 76.9% | 1,842.2 76.1% | 2,273.7 79.7% |
| Operating Expenses | 87.3 | 100.1 | 160.5 | 204.2 | 242.3 | 299.0 | 389.8 | 519.1 | 608.8 | 781.7 | 1,019.4 | 1,111.5 | 1,211.6 | 1,349.5 | 1,470.0 | 1,432.4 | 1,458.1 | 1,570.8 | 1,746.3 | 1,789.5 |
| Research & Development Expenses (R&D) | 56.4 | 66.7 | 78.6 | 93.3 | 115.1 | 147.3 | 214.4 | 302.2 | 354.8 | 461.5 | 634.8 | 661.9 | 610.8 | 696.3 | 715.0 | 628.1 | 628.8 | 649.6 | 746.8 | 747.2 |
| Selling, General & Administrative Expenses (SG&A) | 41.6 | 49.0 | 77.5 | 106.6 | 124.3 | 151.7 | 175.4 | 198.2 | 235.4 | 302.2 | 402.3 | 476.6 | 554.3 | 604.4 | 680.9 | 737.7 | 759.4 | 854.0 | 937.3 | 1,009.0 |
% margin | (64.2) (250.2%) | (24.7) (29.3%) | (57.3) (47.1%) | 39.8 13.4% | 16.4 5.1% | 0.5 0.1% | (33.9) (7.7%) | (110.2) (22.0%) | (156.0) (28.4%) | (92.9) (12.4%) | (110.7) (12.4%) | (803.4) (71.9%) | (14.7) (1.1%) | (123.5) (8.3%) | (125.5) (7.4%) | (96.3) (5.2%) | (60.0) (3.3%) | 57.5 2.7% | 194.4 8.0% | 484.2 17.0% |
| Interest Income | 1.9 | 12.9 | 0.0 | 16.4 | 5.1 | 4.1 | 2.9 | 2.6 | 3.1 | 5.9 | 4.5 | 7.5 | 14.9 | 22.8 | 22.7 | 16.6 | 10.5 | 18.0 | 58.3 | 74.9 |
| Interest Expense | 11.9 | 16.7 | 0.0 | 16.4 | 14.1 | 10.3 | 8.3 | 7.6 | 10.4 | 36.6 | 38.2 | 39.5 | 42.7 | 43.7 | 23.5 | 29.3 | 15.3 | 16.0 | 17.3 | 12.3 |
| Pre-tax Income | (74.3) | (28.5) | (15.1) | 33.4 | 0.6 | (21.5) | (43.6) | (118.3) | (176.5) | (124.9) | (154.7) | (831.1) | (35.9) | (142.7) | (94.8) | (42.3) | (75.4) | 149.6 | 188.6 | 541.8 |
% effective tax rate | 21.9 (29.5%) | 23.1 (81.1%) | 0.7 (4.8%) | 2.6 7.8% | 1.1 186.2% | (227.3) 1,057.7% | 10.2 (23.4%) | (3.9) 3.3% | (0.2) 0.1% | 9.1 (7.3%) | 17.1 (11.0%) | (200.8) 24.2% | 81.2 (226.2%) | (65.5) 45.9% | (71.0) 74.8% | (901.4) 2,129.9% | (11.3) 15.0% | 8.0 5.4% | 20.9 11.1% | 114.9 21.2% |
% margin | (74.3) (289.3%) | (28.5) (33.9%) | (15.8) (13.0%) | 30.8 10.4% | (0.5) (0.2%) | 205.8 54.7% | (53.8) (12.2%) | (114.3) (22.8%) | (176.4) (32.2%) | (134.0) (17.8%) | (171.8) (19.3%) | (630.2) (56.4%) | (117.0) (8.9%) | (77.2) (5.2%) | (23.8) (1.4%) | 854.0 45.9% | (64.1) (3.5%) | 141.6 6.8% | 167.6 6.9% | 426.9 15.0% |
| EPS | (1.08) | (0.34) | (0.16) | 0.31 | (0.00) | 1.99 | (0.48) | (0.95) | (1.28) | (0.92) | (1.07) | (3.80) | (0.67) | (0.44) | (0.13) | 4.75 | (0.35) | 0.76 | 0.89 | 2.13 |
| Diluted EPS | (1.08) | (0.34) | (0.16) | 0.29 | (0.00) | 1.73 | (0.48) | (0.95) | (1.28) | (0.92) | (1.07) | (3.79) | (0.67) | (0.44) | (0.13) | 4.53 | (0.35) | 0.75 | 0.87 | 2.06 |
% margin | (54.5) (212.2%) | (14.9) (17.7%) | (57.3) (47.1%) | 67.4 22.7% | 35.6 11.0% | 17.1 4.5% | (0.2) (0.0%) | (79.8) (15.9%) | (137.4) (25.0%) | (50.0) (6.7%) | (110.7) (12.4%) | (705.5) (63.2%) | 94.8 7.2% | (3.5) (0.2%) | 33.9 2.0% | (5.9) (0.3%) | 48.0 2.6% | 267.5 12.8% | 310.3 12.8% | 650.5 22.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is BioMarin Pharmaceutical Inc.'s EV/Revenue LTM?
As of today, Microsoft Corp's last 12-month EV/Revenue LTM is 4.4x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual EV/Revenue LTM for BioMarin Pharmaceutical Inc. have been 7.5x over the past three years, and 8.3x over the past five years.
2) Is BioMarin Pharmaceutical Inc.'s EV/Revenue LTM Good?
As of today, BioMarin Pharmaceutical Inc.'s EV/Revenue LTM is 4.4x, which is higher than industry median of 3.7x. It indicates that BioMarin Pharmaceutical Inc.'s EV/Revenue LTM is Bad.